Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.

Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action lawsuit has been filed against Capricor Therapeutics for allegedly failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased securities between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.

Cadeler A/S shares aee trading higher after the company reported a year-over-year increase in Q2 financial results and affirmed its FY26 sales guidance above estimates.

Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance was maintained. Other stocks also moved in pre-market trading.